General Information of Drug (ID: DMPXLMB)

Drug Name
Demobesin Drug Info
Synonyms Bombesin antagonist (prostate/breast/NSCL), Biomedica lifesciences; 99mTc-Demobesin-6
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMPXLMB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Bombesin receptor (BS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY-86-7548 DM195JA Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
kuwanon H DMVQDNR Discovery agent N.A. Investigative [4]
bombesin DMDFQ0Y Discovery agent N.A. Investigative [5]
PD 168368 DMFNQEA Discovery agent N.A. Investigative [6]
MK-5046 DMS7C6R Discovery agent N.A. Investigative [7]
bantag-1 DM4OT8M Discovery agent N.A. Investigative [8]
ranatensin DMI7NAF Discovery agent N.A. Investigative [9]
PD 176252 DM7AY6K Discovery agent N.A. Investigative [6]
[(N4-Bzdig)0]BB(7-14) DMD4BSJ Discovery agent N.A. Investigative [10]
neuromedin B DMCXJLH Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bombesin receptor (BS) TTHYDUM NMBR_HUMAN; GRPR_HUMAN; BRS3_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT00989105) Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38).
3 Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72.
4 Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9.
5 Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20.
6 Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86.
7 Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336(2):356-64.
8 Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16.
9 Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20.
10 Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10.
11 Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides. 2015 Oct;72:128-44.